Apple 2003 Annual Report Download - page 109

Download and view the complete annual report

Please find page 109 of the 2003 Apple annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 164

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164

hereafter filed), Product (as defined in Agreement No. IMD001) provided by IBM to Apple directly or indirectly through one or more other
entities during the term of that agreement and through the date of commencement of this Agreement. This Section 11.4 does not reduce or
negate any other right or claim of indemnity that Apple may have under any of the above agreements or any other agreements or statute or
common law without reference to this Section 11.4.
11.5 The foregoing as limited by Section 12.0 states the entire obligations and exclusive remedies of IBM and Apple regarding any third
party claim of infringement relating to any Product sold or Service or Item provided hereunder or, as the case may have been, under that
agreement referenced in Section 11.4.
12.0 LIMITATION OF LIABILITY
12.1 Neither party shall be entitled to special, indirect, incidental, consequential or punitive damages, including lost profits, opportunities
or savings based on any breach or default of the other party, even if such party is informed of their possibility, except (i) [**], and (ii) to the
extent such damages are awarded in a final judgment or settlement covered by Section 11.
12.2 In no event shall either party’s aggregate liability to the other party for damages in connection with all claims relating to this
Agreement exceed the amount of [**], regardless of the form of action (including fundamental breach, negligence, misrepresentation, or other
contract or tort claim), provided that this limitation will not apply to: (i) the amount of any damages for bodily injury (including death) caused
by such party’s negligence or damages to real property and tangible personal property caused by such party’s negligence; and (ii) payments
owed for Products and Services provided hereunder.
This Section 12.2 also applies to any of IBM’s subcontractors and any Authorized Purchasers. It is the maximum for which IBM and its
subcontractors are collectively responsible, and for which Apple and its Authorized Purchasers are collectively responsible.
12.3 Under no circumstances is either party liable to the other for any of the following: (i) third party claims against a party for losses or
damages other than those in Section 11 and 12.2 (i), above; or (ii) loss of, or damage to, records or data. Further under no circumstances will
IBM be liable when the Products or Services are used in conjunction with military, nuclear, automotive or aeronautical applications or medical
implantation or other direct life support applications where malfunction may result in injury, harm or death to persons, or used in any other
ultrahazardous applications
[**] = information redacted pursuant to a confidential treatment request. Such omitted information has been filed separately with the Securities
and Exchange Commission.